{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-008080","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.062000+00:00","generated_at":"2026-06-18T02:36:53.837629+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M","bullets":["Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.","Operating loss of $2.5M vs income of $0.83M in prior year; adjusted EBITDA loss of $1.6M vs positive $1.5M.","Record quarterly bookings; cash on hand $11.6M with no debt; net cash from ops $1.6M in Q3.","R&D spend increased $1.0M (46.8%) to $3.2M, mainly for therapeutic target discovery platform.","CEO expects improved results in fiscal 2024; YTD revenue up 12.6% to $40.8M but operating loss of $2.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-008080","json":"https://secwatch.observer/filing/0001628280-23-008080.json","markdown":"https://secwatch.observer/filing/0001628280-23-008080.md","text":"https://secwatch.observer/filing/0001628280-23-008080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/0001628280-23-008080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/csbr-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:36:53.837629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"950285189447ebffa3b565363db42850664b20b2","claim":"CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2023, ended January 31, 2023 results: revenue $12.8 million.","evidence_excerpt":"Champions Oncology Reports Quarterly Revenue of $12.8 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/0001628280-23-008080-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal 2023, ended January 31, 2023"},{"label":"Revenue","value":"$12.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}